Company
NovaBridge Biosciences (NBP)
Standardized SEC financial data for NovaBridge Biosciences — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001778016 · NASDAQ · Pharmaceutical Preparations.
Gross margin
-900.0%
Net margin
-1000.0%
Revenue growth (YoY)
112.5%
Return on equity
-85.3%
Free cash flow
-¥1.32B
Current ratio
5.67×
EPS (diluted)
¥-7.66
Ratios for fiscal year 2023, standardized from SEC filings.
Income statement
| ¥ | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | ¥1.54B | ¥88.0M | -¥221.6M | ¥27.6M | — | — |
| Cost of revenue |
Balance sheet
| ¥ | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | ¥4.76B | ¥3.52B | ¥3.31B | ¥2.20B | — | — |
| Inventory |
Cash flow
| ¥ | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|
| Operating cash flow | -¥280.7M | -¥868.0M | ¥433.6M | -¥973.1M | -¥1.10B | -¥1.30B |
| Capital expenditures |
Get NBP data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/NBP/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/NBP/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"